Daewoong Pharmaceutical has partnered with Chong Kun Dang for local sales of the gastroesophageal reflux disease (GERD) treatment Fexuclue, the country’s 34th new drug, the company said Monday. Fexuclue is a potassium-competitive acid blocker (P-CAB)-based GERD treatment that is designed to improve the shortcomings of proton pump inhibitor (PPI) drugs, such as slow onset of action and dietary effects. P-CABs ha...